Page 1,569«..1020..1,5681,5691,5701,571..1,5801,590..»

FDA warns of foot, leg amputations with J&J diabetes drug – Reuters

Posted: May 17, 2017 at 1:40 pm

Johnson & Johnson (JNJ.N) is required to add new warnings to its diabetes drug, Invokana, about the risk of foot and leg amputations, the U.S. Food and Drug Administration said on Tuesday.

Final results from two clinical trials showed leg and foot amputations occurred about twice as often in patients with type 2 diabetes treated with Invokana, known also as canagliflozin, as those given a placebo, the FDA said in an announcement posted on its website.

The warnings include a boxed warning, reserved for the most serious possible adverse events, the FDA said.

Invokana belongs to a relatively new class of type 2 diabetes drugs called SGLT-2 inhibitors, which help remove excess blood sugar through urine. Others in the class include Eli Lilly and Co's (LLY.N) Jardiance and AstraZeneca Plc's (AZN.L) Farxiga.

The FDA noted that results of one clinical trial showed that over the course of a year the risk of amputation in patients treated with Invokana was equivalent to 5.9 out of 1,000, compared with 2.8 out of 1,000 for patients given a placebo.

A second trial showed the risk of amputation was equivalent to 7.5 out of every 1,000 patients treated with Invokana compared with 4.2 out of every 1,000 patients given a placebo.

The agency said amputations of the toe and middle of the foot were the most common but that amputations involving the leg, below and above the knee, also occurred.

Untreated type 2 diabetes can cause blindness, nerve and kidney damage and heart disease.

(Reporting by Toni Clarke in Washington and Bill Berkrot in New York; Editing by Lisa Shumaker)

Concert Pharmaceuticals Inc said on Wednesday the U.S. Food and Drug Administration (FDA) imposed a clinical hold on a trial testing the company's drug to treat alopecia areata, a type of hair loss.

MUMBAI India's big drugmakers will need at least five more years to improve their manufacturing standards and data reliability to a level demanded by international regulators, said a senior industry official.

Overweight and obese people who shed a lot of excess pounds may have less damage in their knee joints than their counterparts who dont lose weight, a recent study suggests.

Read more:
FDA warns of foot, leg amputations with J&J diabetes drug - Reuters

Posted in Diabetes | Comments Off on FDA warns of foot, leg amputations with J&J diabetes drug – Reuters

Local teen advocating for diabetes research – Journalscene.com

Posted: May 17, 2017 at 1:40 pm

Cameron Shephard is a local teen supported by her family as she raises awareness for type 1 diabetes.

The 13-year-old self-professed baby of the family with three siblings is a type 1 diabetic, a disease she was diagnosed with when she was 7 years old.

Type 1 diabetes also referred to as juvenile diabetes, though it can develop at any age is a disease in which the pancreas is not producing enough insulin, which regulates blood sugar. There is no known way to prevent Type 1 diabetes, nor is it curable. It is treatable through insulin therapy, delivered by injections or an insulin pump. Patients also regularly check to their blood sugar levels.

Cameron, who plays tennis and will be a freshman at Ashley Ridge High School next year, is trying to advocate for research through funds and awareness, and has a busy summer laid out that consists of talking to congressmen and cycling 100 miles, all to let people know why they need to care about finding a cure for diabetes.

Cameron and her family from Ridgeville refer to May 9 as her Diaversary the date when she was diagnosed.

Her mom, Lisa, a nurse, said no one else in the Shephard family has diabetes. Camerons diagnosis came as a shock to her parents.

Even as a nurse it shocked me how different it is because in nursing school they tell you so much about Type 2 diabetes, Lisa said.

At the time of her diagnosis, Camerons symptoms consisted of her drinking more and using the bathroom more, and she lost a lot of weight. She was treated at MUSC.

She honeymooned for a year a term referring to the period of time following Type 1 diabetes diagnosis when the pancreas is still producing some insulin to reduce insulin needs and assist blood sugar control.

She has endured more than 15,000 needle injections and eight hypoglycemic seizures. December was her last seizure.

Cameron has used a diabetic pump for about four years, though she sometimes goes back to using injections during the summer. She also has a CGM on her arm, which alerts her every five minutes to what her blood sugar level is so she does not have to do finger pricks as much. The CGM sends the alerts to a device which relays the information to Camerons phone, and her parents phones.

However, Cameron is not slowing down.

The teenager has had a JDRF Walk team for five years and is participating in the Ride to Cure Diabetes in September in New York. JDRF stands for the Juvenile Diabetes Research Foundation and their slogan is turning type one into type none.

The ride is a 100-mile cycling event to raise money and awareness for Type 1 diabetes research. It will be her first ride and the second one for Lisa.

Lisa said she first did the ride in 2016 on Amelia Island. She raised about $4,300 and went about 77 miles, but this year they are pledging 100 miles.

Cameron has also met with local congressmen and senators on diabetes-related issues.

Cameron was recently selected to represent South Carolina in the JDRF Childrens Congress this summer in Washington, D.C. She said she had to complete an application process and write a letter to South Carolina congressmen. There are three children representing South Carolina at the Childrens Congress and Cameron is the only one from below Columbia.

Cameron said she wanted to represent South Carolina because you dont hear about diabetes that much so just got to go make sure it is heard up in Washington.

The family will fly out July 24 to Washington for a busy two days consisting of children all of whom are living with Type 1 diabetes meeting with members of Congress to talk about what it is like living with the disease and why research to fund a cure is critical.

Cameron said she is excited and hopes to explain how we need support with everything.

Some children as young as 4 years old are going to Washington. Lisa said it helps put a face to the situation.

They see those kids and see what they have to do andit kind of pulls at their heart strings, she said.

In preparation for Childrens Congress, Cameron has made scrapbooks and a video and shell sit down with congressmen, one on one, and explain what her life is like to stay healthy.

You just got to constantly monitor it and make sure you dont go too low, Cameron said, referring to her blood sugar level, and if you do you got to have to have Skittles or glucose tab(lets) on you at all times.

Cameron carries a bag with her wherever she goes that carries all her diabetic needs. Shell have to sit out for an activity, like tennis, if her blood sugar is too low or too high.

When she grows up Cameron wants to be a pediatric nurse or maybe an endocrinologist. She said she thinks she would be able to relate with the patients.

Were definitely very proud of her, Lisa said. Ive been proud of her from day one when she was diagnosed.

Lisa said it blows her way the Cameron has never gotten down about the disease and maintains a positive attitude.

Some days Im like, Gosh, I hate this disease and shell just be like, Im fine, Lisa said.

Lisa said in Camerons lifetime, she is not sure if a cure will be found, but she thinks research will find ways to at least prevent Type 1 diabetes.

See the original post:
Local teen advocating for diabetes research - Journalscene.com

Posted in Diabetes | Comments Off on Local teen advocating for diabetes research – Journalscene.com

All-diabetes pro cycling team competes in Amgen Tour of California – KSBY San Luis Obispo News

Posted: May 17, 2017 at 1:40 pm

In a sea of professional cyclists in Stage 3 Pismo Beach of the Amgen Tour of California, riders share a common goal of crossing the finish line first. One team, in particular, has a few other things to think about it besides winning.

Team Novo Nordisk is the world's first and only all-diabetic professional racing team. Every racer has type 1 diabetes.

Australian team member, Chris Williams recalls his diagnosis. "I was in Australia doing a raceandI collapsed at the end of astage," said Williams, 35. "I thought it was dehydration so I went to the hospital and that was when I was diagnosed. The doctor told me I shouldn't cycle anymore because bike racing and diabetes is a difficult combination and I would have to give it up. I was pretty devastated."

Many athletes think they won't be able to live life the way they'd hope after diagnosis. Team Novo Nordisk wants to show the world what is possible with diabetes.

"We have riders from all over the world here. Holland, Italy, and Spain. Diabetes is everywhere," said Vassili Davidenko, Team Novo Nordisk manager.

Team Novo Nordisk hopes to inspire, educate, and empower people affected by diabetes.

"You don't have to give up on your dreams because you have diabetes. There is a common myth that diabetes stops a lot of people from a lot of things but it's not true in many cases. We're an example of that," Williams said.

Novo Nordisk's David Lozano was Tuesday's King of the Mountain.

Team Novo Nordisk athletes will compete in more than 500 competitions around the world and is striving to race in the Tour de France by 2021, which is the 100th anniversary of the discovery of insulin.

Originally posted here:
All-diabetes pro cycling team competes in Amgen Tour of California - KSBY San Luis Obispo News

Posted in Diabetes | Comments Off on All-diabetes pro cycling team competes in Amgen Tour of California – KSBY San Luis Obispo News

When OFAB gathered professionals for biotechnology – NIGERIAN TRIBUNE (press release) (blog)

Posted: May 16, 2017 at 7:44 pm

Dr Rose Gidado

Biotechnology is a modern science tool used by most countries to improve agricultural productivity, thereby eliminating hunger and ensuring food security for their populace.

Genetically Modified Organisms (GMOs) is one of the components of biotechnology which is a science tool used to engineer the genes of plants to make them behave in the manner of which they were engineered for.

GMOs have become a topical issue in Nigeria since the country have had problem of providing enough food for the populace. Recently, famine was reported to have reached some parts of the northern Nigeria.

In the quest to ensure food security in the country, some experts have called on the Nigerian government to adopt the new technology of GMOs to increase productivity.

In Nigeria, GMOs have received some criticisms from some groups, arguing the safety of the crops which the genes have been engineered.

Meanwhile, some scientists have said that the GM seeds are like other conventional seeds and does not contain any harmful or toxic contents.

Recently, the Open Forum of Agricultural Biotechnology (OFAB) gathered professionals to brainstorm on how best to convey the message of science to Nigerians.

In Nigeria, farmers who will be the users of this technology if it is adopted in the country are yet to know about the technology, most of them have not heard of the technology.

The Country Coordinator of OFAB, Dr Rose Gidado during the Agricultural Biotechnology and Biosafety Workshop for Professional Bodies Cadre, said the Forum had carried the biotechnology campaign to farmers.

She said the workshop is expected to expand the scope of OFAB and build the capacity of the participants, so that they can understand what the biotechnology is all about.

According to her the objective of the workshop is that we are trying to expand our scope, we are trying to build the capacity of the participants because science is multi faceted, so they need to understand better what we are doing so that they can join in the campaign for GMOs in Nigeria.

Gidado also said that other professional bodies are needed in the campaign, having in mind the huge benefits of this technology to Nigerian populace and the economy.

We need other professional bodies to join us in this campaign because it is all about science. This technology is all about science, it is evidence based, it is important, it can contribute to the socio-economic of Nigeria.

Meanwhile, the Director-General of the National Agricultural Seed Council, Dr Philip Ojo said before the introduction of any Genetically Modified seeds, the local capacity needs to be built.

In this light, the National Biotechnology Development Agency (NABDA), had recently trained about 20 staff of the National Agricultural Seed Council on how to identify or detect GMOs.

The Director General of NABDA, Professor Lucy Ogbadu said Nigeria cannot afford to ignore the technology, adding that another technology which may be more acceptable to Nigerians have been discovered.

She said the new technology which is called gene editing allows the scientist to work within the confines of one genetic material instead of transferring genes from one organism to another.

We cannot afford to ignore this technology, in fact, so much advances have gone beyond where we started on genetic modification, they developed what is called gene editing and we hope that gene editing will be more acceptable to Nigeria.

Explaining what gene editing is, Professor Ogbadu said we are working within the confines of the genetic materials of one organism; we are not bringing in anything from outside into the organism, so we hope that this will be more acceptable to our people.

On the acceptability of the technology, Dr Gidado said the acceptance level in Nigeria is encouraging, more people are talking for the technology, people are beginning to see why we need it.

She further said that they are carrying the farmers along in their campaign, adding that in 2 or 3 years time, the commercialisation of BT cotton and BT cowpea will commence.

One of the environmental advantage of this technology is that less chemicals and pesticides will be used in the farm, leading to less pollution of the environment with fertilizers and chemicals.

Professor Ogbadu in her presentation a the workshop said the technology has increased environmental protection through the reduced use of pesticides and toxic chemicals.

She also said GMOs improves nutrition for people, increase quality of yields, increase farm profitability through reduced cost and new product opportunity.

Much have been said about this technology, some countries have adopted this technology and used it to advance their food production. It is important that the Nigerian government look for other means to upscale our food production.

GMOs among other biotechnology is a scientific method to improve food production in Nigeria, increase yield and practice agriculture as a business, which will in turn put money in the bags of farmers and contribute the nations GDP.

Continued here:
When OFAB gathered professionals for biotechnology - NIGERIAN TRIBUNE (press release) (blog)

Posted in Biotechnology | Comments Off on When OFAB gathered professionals for biotechnology – NIGERIAN TRIBUNE (press release) (blog)

BIO Statement on the Passing of Biotechnology Giant Henri Termeer … – Business Wire (press release)

Posted: May 16, 2017 at 7:43 pm

WASHINGTON--(BUSINESS WIRE)--Henri Termeer, who passed away at the age of 71, was a founding father of modern biotechnology. He brought to his work, and to his life, a passion, a vision and a perseverance to bring ground-breaking medical innovations to those suffering from rare diseases.

Through his work, Termeer became a mentor and a role model for biotechnology entrepreneurs around the globe. The culture he created at Genzyme, and at the various institutions he worked for throughout his career, was widely seen as the gold standard for patient-focused drug development. He was a master at creating cultures where great science and great people could flourish. As the Boston Globe aptly noted, Termeer had magnetism and warmth, and a deft ability to harness top talent toward a common goal.

Termeer, who was a larger-than-life figure across the biotechnology field, was instrumental in the founding of BIO in 1993, serving as its first vice chair for health. He was named Chairman of the organization in 1996. During his tenure as Chair of BIO, and in the years that followed, Termeer was a key catalyst in the growth of the organization and in establishing BIOs position at the forefront of key policy and regulatory debates. He was an active member of BIOs Board of Directors since its founding until his death, with only a short break in his tenure. Termeer served on BIOs Executive Committee from 1993 to 2000.

Following are statements from leadership at the Biotechnology Innovation Organization (BIO):

Few people in our industry have had as profound an impact as Henri Termeer on the science of biotechnology and the patients who depend on it, said Jim Greenwood, President and CEO of BIO. He had a unique ability to inspire the men and women around him. Henri certainly was a brilliant businessman and a charismatic leader, but his burning passion was to do the unthinkable to innovate and to treat and cure rare diseases that others believed too difficult to tackle. Henri's love of his profession and the people in it was contagious. He taught us that even though our companies were sometimes competitors, our industry must speak with a united voice in the corridors of power. He was a founding father of BIO and thus the thriving ecosystem the biotechnology community enjoys today is another central part of his legacy. Henri was admired, respected and loved by all of us who were fortunate enough to know him as a colleague, a teacher, and a friend. He is an irreplaceable talent who will be long remembered and sorely missed.

Henri Termeer was a giant, said Ron Cohen, President & CEO of Acorda Therapeutics and Chair of BIO. He has left us much too soon. High among his many legacies are the tens of thousands of patients and their families who have benefited from Genzymes innovations, and the scores of biotechnology professionals whom he mentored and who have gone on to be leaders at other companies.

I had the honor of having worked at Genzyme and calling Henri Termeer amentor, said Paul Hastings, Chairman and CEO of OncoMed Pharmaceuticals and Vice Chair of BIO. He taught us all to be tough and business minded, while simultaneously taking into account how every decision impacted every person in the organization that was part of making Genzyme what it was. His focus on always doing the right thing for people and the business was something truly special. We all lost a great friend, a great mentor and awonderful role model.

From 1993-1998, Hastings served as Vice President, Global Marketing, Genzyme Therapeutics, President of Genzyme Europe and President of Genzyme Therapeutics.

"Henri has left us far too soon, but his legacy and contributions to our industry and patients with rare diseases will last forever, said John Maraganore, CEO of Alnylam Pharmaceuticals. Indeed, Henri pioneered the advancement of innovative medicines for orphan disease and inspired other companies and entrepreneurs to follow. He will be deeply missed."

"As an industry leader Henri was unparalleled and unrivaled, said Jeremy Levin, chairman and CEO of Ovid Therapeutics. As a mentor and friend, he was a foundational component of my business philosophy and career. He will be mourned and deeply missed but never forgotten."

About BIO

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling innovations transforming our world and the BIO Newsletter is the organizations bi-weekly email newsletter. Subscribe to the BIO Newsletter.

Upcoming BIO Events

See more here:
BIO Statement on the Passing of Biotechnology Giant Henri Termeer ... - Business Wire (press release)

Posted in Biotechnology | Comments Off on BIO Statement on the Passing of Biotechnology Giant Henri Termeer … – Business Wire (press release)

Forge Therapeutics Attracts Biotechnology Leaders To Join … – PR Newswire (press release)

Posted: May 16, 2017 at 7:43 pm

"Forge is a very exciting, emerging life science company its novel platform and programs, its highly efficient business model, and its creative capitalization all attracted me to join the Board at such a pivotal time in the company's evolution," said John Schmid. "I look forward to providing strategic, operational and financial guidance to the management team in the coming years."

Dr. Worland added, "Multi-drug resistant bacteria 'superbugs' pose a very serious threat to human health and Forge's novel antibiotic program provides a promising solution to this global problem. I am honored to join the Forge Board and excited to work with its talented management team, advisors, and alliance and government partners as the company and technology platforms mature."

About the Forge Board of Directors

Forge's Board of Directors is a well-balanced composition of San Diego biotechnology industry veterans, global drug development experts and corporate finance leaders.

About Forge Therapeutics

Forge Therapeutics is a privately-held biopharmaceutical companydeveloping novel antibiotics to treat multi-drug resistant bacteria, or 'superbugs,' that have ignited a global health epidemic. With its proprietary chemistry approach, Forge develops small molecule inhibitors targeting metalloenzymes. Forge's lead effort is focused on LpxC, a zinc metalloenzyme found only in Gram-negative bacteria and which is essential for bacteria to grow. Forge has discovered novel small molecule inhibitors of LpxC that are potentin vitro, efficaciousin vivo, and effective against drug resistant Gram-negative bacteria 'superbugs.' To complement its innovative approach to drug discovery, Forge hasa capital efficient business model that utilizes a mix of non-dilutive and traditional funding sources to advance itsprograms, including LpxC. Forge has formed a strategic alliance with leading drug discovery alliance and development partnership company Evotec AG and has been awarded multiple government awards to address the global 'superbug' epidemic. In addition, Forge has amassed a rich intellectual property estate on metalloprotein inhibitors to protect its technology and pipeline. For further information, please visit the company's websitewww.ForgeTherapeutics.com and follow us on Twitter @ForgeThera.

Forge Company Contact:Info@ForgeTherapeutics.com

Forge Media Contact:Amy Conrad Juniper Point amy@juniper-point.com 858-366-3243

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/forge-therapeutics-attracts-biotechnology-leaders-to-join-expanded-board-of-directors-300458043.html

SOURCE Forge Therapeutics, Inc.

http://www.forgetherapeutics.com

Read more here:
Forge Therapeutics Attracts Biotechnology Leaders To Join ... - PR Newswire (press release)

Posted in Biotechnology | Comments Off on Forge Therapeutics Attracts Biotechnology Leaders To Join … – PR Newswire (press release)

Bookmarks on Stem Cell Genes Preserve Cell Identity – Cornell Chronicle

Posted: May 16, 2017 at 7:43 pm

Stem cells preserve their identities after cell division by using a series of protein bookmarks on their genes, according to new research published by scientists at Weill Cornell Medicine. The results may further the understanding of how certain diseases like cancer develop and could have broad clinical implications for preventing disease.

Pluripotent stem cells (PSCs) are cells that have the ability to transform into any kind of cell in the body. What type of cell each stem cell becomes called cell identity is determined by a tightly-controlled system regulated by various proteins. As these cells divide by mitosis, each so-called daughter cell produced should be the same type as its cell of origin. But during mitosis the control system is briefly disrupted, creating a window in which a cell can forget its identity and transform into a different kind of cell.

Dr. Effie Apostolou

If a cell doesnt remember what its supposed to be, it can transform into something else, even a malignant cell, saysDr. Effie Apostolou, an assistant professor of molecular biology in medicine and member of theSandra and Edward Meyer Cancer Centerat Weill Cornell Medicine. Understanding how this process is controlled is fundamental to understanding how many diseases arise.

In a paper published May 16 in Cell Reports, Dr. Apostolou and her team found that cell identity is preserved in pluripotent stem cells through a series of small modifications in proteins known as bookmarks on the cells genes. These bookmarks do not change during mitosis. So when the cell resumes its functions, such as transcription, after mitosis, this bookmark serves as a checkpoint to make sure that this process happens properly, Dr. Apostolou said. In this way, PSCs ensure that daughter cells are the same as their mother cells.

The researchers identified some proteins that were possible candidates for bookmarks and then removed those proteins from cells during the critical window in mitosis. If indeed this time window and the presence of these proteins are critical during mitosis, then the cell identity will be challenged, Dr. Apostolou said.

They found that when these mitotic bookmarks were degraded in PSCs, the cells were unable to maintain their identities: they did not reliably divide into the same kind of cell generation after generation. This tells us that these bookmarks are an important mechanism for keeping stem cells working properly, Dr. Apostolou said.

Because pluripotent stem cells hold great promise for prevention and treatment of many diseases, this finding is key, she said. Understanding cell identity is fundamental to understanding disease, as many, including cancer and some neurological diseases, are the result of cell identity being lost.

Mitosis can be either a crisis for cell identity or an opportunity for a new identity to arise she said. If we understand more about how cells maintain their identities during this process, we will better understand tumor formation and we may even be able to push stem cells into an identity that is therapeutically relevant for a given disease.

See original here:
Bookmarks on Stem Cell Genes Preserve Cell Identity - Cornell Chronicle

Posted in Cell Medicine | Comments Off on Bookmarks on Stem Cell Genes Preserve Cell Identity – Cornell Chronicle

Single cell focus reveals hidden cancer cells – Medical Xpress

Posted: May 16, 2017 at 7:43 pm

May 16, 2017 Single cell focus reveals hidden cancer cells. Credit: Shutterstock

Researchers have found a way to identify rogue cancer cells which survive treatment after the rest of the tumour is destroyed, by using a new technique that enables them to identify and characterise individual cancer cells.

Recent breakthroughs are revolutionising cancer treatment, enabling doctors to personalise chemotherapy for each patient. However, although these new treatments are often highly effective, all too often the cancer grows back, eventually causing relapse.

An international research team, led by Professors Adam Mead and Sten Eirik Jacobsen at the University of Oxford and Karolinska Institutet in Sweden, have found a way to identify rogue cancer cells which survive treatment after the rest of the tumour is destroyed, by using a new technique that enables them to identify and characterise individual cancer cells.

Professor Adam Mead of Oxford University's Radcliffe Department of Medicine, said: 'It is increasingly recognised that tumours contain a variety of different cell types, including so-called cancer stem cells, that drive the growth and relapse of a patient's cancer. These cells can be very rare and extremely difficult to find after treatment as they become hidden within the normal tissue.

'We used a new genetic technique to identify and analyse single cancer stem cells in leukaemia patients before and after treatment. We found that even in individual cases of leukaemia, there are various types of cancer stem cell that respond differently to the treatment. A small number of these cells are highly resistant to the treatment and are likely to be responsible for disease recurrence when the treatment is stopped. Our research allowed us uniquely to analyse these crucial cells that evade treatment so that we might learn how to more effectively eradicate them.

'This technique could be adapted to analyse a range of different cancers to help predict both the likely response to treatment, and the risk of the disease returning in the future. This should eventually enable treatment to be tailored to target each and every type of cancer stem cell that may be present.'

Molecularly targeted therapies for cancer frequently induce impressive remissions, however, complete disease elimination remains rare, and patients remain at risk of disease relapse. At a cellular level this is likely to reflect differences between individual cancer cells, so-called intratumoural heterogeneity, which underlies this differential response to treatment.

The researchers from the Weatherall Institute of Molecular Medicine at Oxford's Radcliffe Department of Medicine used a technique called single-cell analysis to study thousands of individual cancer cells in a type of blood cancer called chronic myeloid leukemia (CML) before and after treatment. Being able to identify each subpopulation using this single cell analysis technique will be an important step towards tailoring treatment to each patient.

Explore further: Proportion of cancer stem cells can increase over the course of cancer treatment

More information: Alice Giustacchini et al. Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia, Nature Medicine (2017). DOI: 10.1038/nm.4336

Stem cells in the bone marrow constantly give rise to new blood cells and are responsible for the maintenance of all vital blood components. However, errors during proliferation can change stem cell properties and cause tumours ...

Existing chemotherapy approaches treat cancer by targeting cells that are actively multiplying and have a high metabolic rate. However, cancer stem cells can escape this targeting, leading to chemotherapy-resistant cancer ...

The gene mutations driving cancer have been tracked for the first time in patients back to a distinct set of cells at the root of cancer cancer stem cells. The international research team, led by scientists at the University ...

A new study at the University of York has shown that a standard hormone supplement, used to boost energy levels in prostate cancer patients following radiotherapy, could potentially increase the chances of the cancer returning.

New research is shedding light on how leukaemia cells can survive cancer treatment, suggesting new possibilities for stopping them in their tracks.

A new method to take the DNA fingerprint of individual cancer cells is uncovering the true extent of cancer's genetic diversity, new research reveals.

Researchers have found a way to identify rogue cancer cells which survive treatment after the rest of the tumour is destroyed, by using a new technique that enables them to identify and characterise individual cancer cells.

Cells are constantly turning proteins on and off via molecular switchesphosphate moleculesthat have become common drug targets. in a new study, lung cancer tumors were prevented in mice by a novel small molecule that ...

A study recently published in Nature Communications shows that breast cancer cells undergo a stiffening state prior to becoming malignant. The discovery, made by a research team led by Florence Janody, from Instituto Gulbenkian ...

For women who miss a breast screening appointment, giving a fixed date and time for a new appointment could improve poor attendance and be a cost-effective way to shift national participation trends, according to an analysis ...

'Tumour-trained' immune cells - which have the potential to kill cancer cells - have been seen moving from one tumour to another for the first time. The new findings, which were uncovered by scientists at Australia's Garvan ...

New diagnoses for two types of skin cancer increased in recent years, according to a Mayo Clinic-led team of researchers.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

View original post here:
Single cell focus reveals hidden cancer cells - Medical Xpress

Posted in Cell Medicine | Comments Off on Single cell focus reveals hidden cancer cells – Medical Xpress

Texas leans into unproven stem cell treatments, to the dismay of scientists – STAT

Posted: May 16, 2017 at 7:42 pm

H

e made the emotional plea to his colleagues: Pass this bill.

It might give somebody like my wife a chance to walk, Texas Representative Drew Springer said through tears late Thursday at the state Capitol in Austin. Id trade every one of my bills Ive passed, every single one of them, to get the chance to hear HB 810.

HB 810 is one of three bills being considered in the Texas Legislature that would make it easier for sick people to try unproven therapies at their own risk, and cost. Springers bill would allow clinics offering unapproved stem cell treatments to treat patientsin Texas. HB 661 would permit people with chronic illness to get therapies in early-stage clinical trials not just terminally ill patients, as the states current right-to-try law does. And HB 3236 would allow companies to charge patients for unproven therapies.

advertisement

The debate in Texas echoes a national discussion over how much access patients should have to experimentaldrugs. For the lawmakers supporting the measures, the issue is about the ability to make ones own decisions about health care and not let bureaucracy get in the way of that. But for stem cell researchers and many patient advocates, the bills are dangerous; they make it easier for people to be fleeced or potentially harmed by treatments with little evidence suggesting that they work, orare safe.

With patients demanding experimental drugs, right to try is becoming the law of the land

When patients get desperate, they have a capacity to suspend disbelief, said Sean Morrison, a stem cell biologist at the University of Texas Southwestern Medical Center in Dallas. When offered the opportunity of a therapy they believe in, even without data and if the chances of benefit are low, theyll fight for access to that therapy. The problem is there are fraudulent stem cell clinics that have sprung up to exploit that.

The personal appeal from Springer, whose wife is paralyzed from the waist down, has worked, at least for now. HB 810 and the other two billspassed the House on Friday with no opposition. They have now moved to the Senate, which only has two weeks to take them up before the Legislature breaks on May 29 for two years.Governor Greg Abbott has indicated he supports HB 810.

Stem cells hold tremendous promise as therapies, but experts say they are still experimental and are not ready to be widely deployed outside regulated and limited trials. Yet clinics offering unproven, and sometimes dangerous, stem cell treatments to eager patients have proliferated around the country in recent years even without the state law, there areat least 71 clinics selling unapproved stem cell therapies in Texas alone.Stem cell scientists fear that the Texas bill would lend legitimacy to the field, provide false hope to patients, and even embolden hucksters touting stem cells as miracle cures for everything from diabetes to multiple sclerosis to spinal injuries.

It may sound like an appealing idea to allow seriously ill patients accelerated access to experimental therapies, Sally Temple, the president of the International Society for Stem Cell Research, wrote to Texas lawmakers this month. But in the absence of full clinical testing, these bills will allow snake oil salesmen to sell unproven and scientifically dubious therapies to desperate patients.

When offered the opportunity of a therapy they believe in, even without data and if the chances of benefit are low, theyll fight for access to that therapy.

Sean Morrison, stem cell biologist at the University of Texas Southwestern Medical Center

In the letter, Temple also wrote that the bills would cost more lives than they save and will undermine confidence in Texas medical system. She cited the three women who were blinded after receiving stem cell procedures at a Florida clinic. At least one of the women thought she was participating in a clinical trial.

For the most part, stem cell clinics and their claims are unchecked. Theyhave largely avoided regulatory scrutiny because they typically take a patients own stem cells and inject them back into the person, meaning the cells are considered minimally manipulated,taken, perhaps, from belly fat, purified, and injected near the persons knee. Plus,stem cell clinics typically do not publish data about their interventions and their patients results, so outside researchers have not been able to verify even their supposed successes.

If these clinics really did have a cure for something, you think they would collect systematic data and publish it in a journal, so people would know, Morrison said.

In a phone interview the morning after his speech, Springer, a Republican who represents a North Texas district, said he wanted to maintain some level of oversight for stem cell therapies and that the state attorney generals office or health department could step in should problems arise. But he said he leaned toward letting people have treatments they think can help them, especially because the drug approval process takes so long.

Stem cell clinics hawking unproven therapies sprout up across US

Springers wife was injured in a diving accident when they were dating and has been in a wheelchair since. He said they stored cord blood from when one of their children was born 16 years ago in hopes that the stem cells from that could one day help his wife. For now, he wants the Texans who head to places like Panama and China for stem cell therapies to be able to get them in their home state, under state law.

We do have a responsibility not to let every snake oil salesman come in, Springer said, but when we do have these rays of hope, we have to make sure theyre available.

Springer is only an author of HB 810, not the other two measures. The lead authors of the other two measures, Republican Representative Tan Parker for HB 661, and Republican Representative Kyle Kacal for HB 3236, did not respond to requests for comment.

HB 810 would give some legal recognition to the stem cell clinics that are already operating in Texas, an indication that troubles some researchers. Paul Knoepfler, a stem cell scientist at the University of California, Davis, co-led a nationwide survey that found Texas has more stem cell clinics than many other states, but that the businesses were part of a national pattern. But he said he hasnt seen other states consider the types of policies Texas is weighing now.

The kind of murky status quo that exists now for regulating stem cell clinics is quite different than there being laws on the books that explicitly say that what the clinics are doing is legal at the state level, Knoepfler wrote in an email.

A few years ago, in one famous case, a Houston company, Celltex Therapeutics, moved its treatment operations to Mexico after a warning from the Food and Drug Administration. But experts wonder if the FDA would take such an action again if the bills became law in Texas, even though the agency would still maintain its authority to do so under federal law. That concern also stems from the feeling that the regulation-averse Trump administration wouldnt endorse such actions, especially because Vice President Mike Pence is a proponent of right-to-try measures and Energy Secretary Rick Perry, the former Texas governor, credits a stem cell treatment from Celltex for helping relieve his back problems.

Perrys story and Springers emotional testimony highlight the uphill battle scientists have faced in recent years as right-to-try laws have been passed around the country. Powerful personal stories of patients cured by unapproved drugs or who die before they can get access to an experimental drug have swayed many lawmakers from both parties.

They look at us like were the devil, which pisses me off because were doing it the right way, said David Bales, the chairman of Texans for Cures, a stem cell research advocacy group that opposes the three bills as written.

Baless group wants to fund legitimate clinical trials involving stem cell treatments to help determine in what ways the cells can help patients. But for now, its top target is stopping HB 3236, which would open the door to patients paying for experimental therapies. Virtually all reputable clinical trials provide experimental treatments to patients at no cost and ofteneven pay participants for their effort.

We dont think that patients in the most vulnerable positions should pay for an unproven drug, Bales said.

Springer, the state representative, said he had not spoken to the governor about HB 810. But Abbott, who has been paralyzed from the waist down since a 1984 accident, when a tree branch fell on him while he was out for a run, tweeted a message of support to Springer early last Friday.

I look forward to signing HB 810, the tweet said.

Andrew Joseph can be reached at andrew.joseph@statnews.com Follow Andrew on Twitter @DrewQJoseph

Trending

Drug used to halt puberty in children may cause

Drug used to halt puberty in children may cause lasting health problems

Why are doctors plagued by depression and suicide? A

Why are doctors plagued by depression and suicide? A crisis comes into focus

Googles bold bid to transform medicine hits turbulence under

Googles bold bid to transform medicine hits turbulence under a divisive CEO

Recommended

Why nabbing former FDA commissioner Robert Califf would be

Why nabbing former FDA commissioner Robert Califf would be a win for Verily

Patients fare worse with older doctors, study finds

Patients fare worse with older doctors, study finds

Q&A: Bringing oncology discussions to a broader audience

Q&A: Bringing oncology discussions to a broader audience

Continue reading here:
Texas leans into unproven stem cell treatments, to the dismay of scientists - STAT

Posted in Cell Therapy | Comments Off on Texas leans into unproven stem cell treatments, to the dismay of scientists – STAT

ReNeuron wins 1.8 million for cell therapy development – PharmaTimes

Posted: May 16, 2017 at 7:42 pm

ReNeuron has won a 1.8 million grant from Innovate UK to advance its next generation commercial cell therapy manufacturing capabilities.

The award will support work being undertaken by the UK stem cell company and the Cell & Gene Therapy Catapult.

In particular it will fund key process development activities relating to up-scaled commercial manufacture of ReNeurons cell therapy candidates.

Sharon Grimster, general manager, Wales, at ReNeuron, said: We are delighted to have won this prestigious and highly competitive grant from Innovate UK. It enables us to further pursue and optimise our cell therapy manufacturing processes as our therapeutic programmes get closer to market.

The grant award will also assist ReNeuron in the execution of its strategy to ultimately bring the manufacture of its cell therapy candidates in-house to meet demand following market approval.

ReNeurons lead stem cell candidate is for patients left disabled by a stroke. Last year a Phase I trial of showed its CTX cell therapy candidate improved neurological function in patients with stable motor disability following a stroke for at least 24 months.

More here:
ReNeuron wins 1.8 million for cell therapy development - PharmaTimes

Posted in Cell Therapy | Comments Off on ReNeuron wins 1.8 million for cell therapy development – PharmaTimes

Page 1,569«..1020..1,5681,5691,5701,571..1,5801,590..»